$STXS
Stereotaxis, Inc. Stock $stxs

$stxs Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222031744 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$7.301M	$7.657M	$9.106M
YoY Change	-11.4%	-15.92%	4.63%
Cost Of Revenue	$2.992M	$3.090M	$4.372M
YoY Change	30.59%	-29.32%	8.61%
Gross Profit	$4.309M	$4.567M	$4.735M
YoY Change	-27.57%	-3.54%	1.2%
Gross Profit Margin	59.02%	59.64%	51.99%
Selling, General & Admin	$6.365M	$6.801M	$6.855M
YoY Change	-4.78%	-0.78%	59.83%
% of Gross Profit	147.71%	148.92%	144.78%
Research & Development	$2.400M	$2.818M	$2.500M
YoY Change	-8.21%	12.73%	28.02%
% of Gross Profit	55.7%	61.7%	52.8%
Depreciation & Amortization	$131.0K	$104.0K	$26.28K
YoY Change	401.92%	295.74%	-6.74%
% of Gross Profit	3.04%	2.28%	0.56%
Operating Expenses	$8.765M	$9.619M	$9.354M
YoY Change	-5.74%	2.83%	49.88%
Operating Profit	-$4.456M	-$5.052M	-$4.620M
YoY Change	33.02%	9.35%	195.57%
Interest Expense	$302.0K	$135.0K	$1.260K
YoY Change	-6826.06%	10614.29%	-112.69%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$4.154M	-$4.917M	-$4.619M
YoY Change	23.84%	6.46%	193.62%
Income Tax
% Of Pretax Income
Net Earnings	-$4.492M	-$4.917M	-$4.619M
YoY Change	33.92%	6.46%	193.62%
Net Earnings / Revenue	-61.53%	-64.22%	-50.72%
Basic Earnings Per Share		-$0.07	-$0.07
Diluted Earnings Per Share	-$0.06	-$0.07	-$61.01K
COMMON SHARES
Basic Shares Outstanding	74.84M shares	74.79M shares	75.70M shares
Diluted Shares Outstanding		76.10M shares	75.70M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.43M	$30.94M	$40.24M
YoY Change	-26.61%	-23.12%	-7.69%
Cash & Equivalents	$8.586M	$30.94M	$40.24M
Short-Term Investments	$19.84M
Other Short-Term Assets	$1.850M	$1.903M	$4.240M
YoY Change	-34.17%	-55.11%	109.35%
Inventory	$7.876M	$8.161M	$3.855M
Prepaid Expenses
Receivables	$5.090M	$5.077M	$5.073M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$43.25M	$46.08M	$53.41M
YoY Change	-15.84%	-13.73%	-0.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.831M	$3.409M	$7.556M
YoY Change	45.55%	-54.89%	151.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$952.0K	$1.108M	$953.4K
YoY Change	-22.58%	16.21%	271.46%
Total Long-Term Assets	$10.17M	$9.996M	$8.510M
YoY Change	5.94%	17.47%	161.39%
TOTAL ASSETS
Total Short-Term Assets	$43.25M	$46.08M	$53.41M
Total Long-Term Assets	$10.17M	$9.996M	$8.510M
Total Assets	$53.41M	$56.08M	$61.92M
YoY Change	-12.42%	-9.44%	8.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.270M	$3.941M	$3.937M
YoY Change	-21.94%	0.1%	151.01%
Accrued Expenses	$3.306M	$3.211M	$3.021M
YoY Change	30.78%	6.27%	-42.25%
Deferred Revenue	$7.342M	$8.043M
YoY Change	16.97%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.29M	$15.55M	$13.84M
YoY Change	7.76%	12.36%	2.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$51.00K	$168.0K	$7.921M
YoY Change	-76.71%	-97.88%	480.06%
Total Long-Term Liabilities	$51.00K	$168.0K	$0.00
YoY Change	-76.71%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.29M	$15.55M	$13.84M
Total Long-Term Liabilities	$51.00K	$168.0K	$0.00
Total Liabilities	$21.48M	$22.72M	$21.76M
YoY Change	-0.36%	4.41%	31.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$517.0M	-$512.8M
YoY Change	3.67%
Common Stock	$75.00K	$75.00K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.35M	$27.77M	$40.16M
YoY Change
Total Liabilities & Shareholders Equity	$53.41M	$56.08M	$61.92M
YoY Change	-12.42%	-9.44%	8.38%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$4.492M	-$4.917M	-$4.619M
YoY Change	33.92%	6.46%	193.62%
Depreciation, Depletion And Amortization	$131.0K	$104.0K	$26.28K
YoY Change	401.92%	295.74%	-6.74%
Cash From Operating Activities	-$2.552M	-$2.533M	-$619.4K
YoY Change	24.13%	308.96%	28.24%
INVESTING ACTIVITIES
Capital Expenditures	$369.0K	-$205.0K	-$887.9K
YoY Change	-202.8%	-76.91%
Acquisitions
YoY Change
Other Investing Activities	-$19.72M
YoY Change
Cash From Investing Activities	-$20.09M	-$205.0K	-$887.9K
YoY Change	5495.64%	-76.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	61.00K	48.00K	133.7K
YoY Change	420.03%	-64.11%	84.09%
NET CHANGE
Cash From Operating Activities	-2.552M	-2.533M	-619.4K
Cash From Investing Activities	-20.09M	-205.0K	-887.9K
Cash From Financing Activities	61.00K	48.00K	133.7K
Net Change In Cash	-22.58M	-2.690M	-1.374M
YoY Change	839.44%	95.84%	234.75%
FREE CASH FLOW
Cash From Operating Activities	-$2.552M	-$2.533M	-$619.4K
Capital Expenditures	$369.0K	-$205.0K	-$887.9K
Free Cash Flow	-$2.921M	-$2.328M	$268.6K
YoY Change	72.13%	-966.88%	-155.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001289340
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	STXS	Non Cash Interest NonCashInterest		usd
	STXS	Increase Decrease Compensating Cash Arrangement IncreaseDecreaseCompensatingCashArrangement		usd
CY2022Q3	us-gaap	Sublease Income SubleaseIncome		usd
	us-gaap	Sublease Income SubleaseIncome		usd
CY2021Q4	us-gaap	Contractual Obligation ContractualObligation		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36159
	dei	Entity Registrant Name EntityRegistrantName	STEREOTAXIS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3120386
	dei	Entity Address Address Line1 EntityAddressAddressLine1	710 North Tucker Boulevard
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 110
	dei	Entity Address City Or Town EntityAddressCityOrTown	St. Louis
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	63101
	dei	City Area Code CityAreaCode	(314)
	dei	Local Phone Number LocalPhoneNumber	678-6100
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	STXS
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74844714	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30938000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38739000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	618000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	454000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	227000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	180000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5077000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5406000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	8161000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4433000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1285000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2356000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	46079000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	51388000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3409000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2632000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	875000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	952000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5479000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5735000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	233000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	278000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3211000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2528000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8043000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	22387	shares
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5584000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5584000	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Assets Assets	56075000	usd
CY2021Q4	us-gaap	Assets Assets	60985000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3941000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4189000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6277000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	359000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	268000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	15554000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13262000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1416000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2238000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5586000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5842000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	168000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	219000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	22724000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	21561000	usd
CY2022Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	22386	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74832278	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74618240	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5610121	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5610121	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	6000	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	6000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	75000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	75000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	540706000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	532641000	usd
CY2022Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4015	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4015	shares
CY2022Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	206000	usd
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	206000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-512814000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-498676000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27767000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	33840000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56075000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60985000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7657000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9106000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20846000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26780000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	3090000	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	4372000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	6685000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	9498000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	4567000	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	4734000	usd
	us-gaap	Gross Profit GrossProfit	14161000	usd
	us-gaap	Gross Profit GrossProfit	17282000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2818000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2500000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8158000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7584000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3111000	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2910000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14320000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9539000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9337000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8902000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3690000	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	135000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3944000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10986000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10335000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	9619000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	9354000	usd
	us-gaap	Operating Expenses OperatingExpenses	28481000	usd
	us-gaap	Operating Expenses OperatingExpenses	26821000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5052000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4620000	usd
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	182000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-5000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2183000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4917000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4619000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14138000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7361000	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	339000	usd
CY2021Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	338000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1005000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1007000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5256000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4957000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15143000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8368000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76100007	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75700389	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75977920	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75476381	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76100007	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75700389	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75977920	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75476381	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	36466000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	108000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	27000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-6000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	34573000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2597000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4619000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2695000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4917000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	26000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27767000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	34624000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	447000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	6753000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	29941000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	22000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7361000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	89000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	21000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	34573000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	33840000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	7906000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14138000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	92000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27767000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14138000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7361000	usd
	us-gaap	Depreciation Depreciation	298000	usd
	us-gaap	Depreciation Depreciation	80000	usd
	STXS	Operating Lease Expense Income OperatingLeaseExpenseIncome	90000	usd
	STXS	Operating Lease Expense Income OperatingLeaseExpenseIncome	111000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7906000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6753000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2183000	usd
	STXS	Non Cash Interest NonCashInterest	24000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-329000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1558000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3280000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	559000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1071000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	668000	usd
	STXS	Increase Decrease Compensating Cash Arrangement IncreaseDecreaseCompensatingCashArrangement	1000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-45000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-55000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	687000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1492000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-19000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-647000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1199000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2650000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-51000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	85000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5863000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1727000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5256000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2009000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	201000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2009000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-201000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	159000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	536000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	159000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	536000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7713000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1392000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40144000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43940000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32431000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42548000	usd
	STXS	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	163000	usd
	STXS	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	830000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30938000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40243000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	618000	usd
CY2021Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1605000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	875000	usd
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	700000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	32431000	usd
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	42548000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80E_eus-gaap--NatureOfOperations_zsQsfgbFMbEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1. <span id="xdx_825_zmQk60BrY9Ca">Description of Business</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stereotaxis is a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention. We design, manufacture and market robotic systems, instruments and information systems for the interventional laboratory. Our proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Direct control of the tip of an interventional device, in contrast to all manual hand-held devices that are controlled from their handle, can improve the precision, stability, reach and safety of these devices during procedures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our primary clinical focus has been electrophysiology, specifically cardiac ablation procedures for the treatment of arrhythmias. Cardiac ablation has become a well-accepted therapy for arrhythmias and a multi-billion-dollar medical device market with expectations for substantial long-term growth. We have shared our aspiration and a product strategy to expand the clinical focus of our technology to several additional endovascular indications including coronary, neuro, and peripheral interventions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is substantial real-world evidence and clinical literature for Robotic Magnetic Navigation in electrophysiology. Hundreds of electrophysiologists at over one hundred hospitals globally have treated over 100,000 arrhythmia patients with our robotic technology. Clinical use of our technology has been documented in over 400 clinical publications. Robotic Magnetic Navigation is designed to enable physicians to complete more complex interventional procedures with greater success and safety by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied computer-controlled magnetic fields that govern the motion of the working tip of the catheter, resulting in improved navigation. The more flexible atraumatic design of catheters driven using magnetic fields may reduce the risk of patient harm and other adverse events. Performing the procedure from a control cockpit enables physicians to complete procedures in a safe location protected from x-ray exposure, with greater ergonomics, and improved efficiency. We believe these benefits can be applicable in other endovascular indications where navigation through complex vasculature is often challenging or unsuccessful and generates significant x-ray exposure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our primary products include the <i>Genesis RMN </i>System, the <i>Odyssey </i>Solution, and other related devices. We also offer to our customers the Stereotaxis Imaging Model S x-ray System and other accessory devices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <i>Genesis RMN System</i> is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter, resulting in improved navigation, efficient procedures, and reduced x-ray exposure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <i>Odyssey Solution</i> consolidates lab information onto one large integrated display, enabling physicians to view and control all the key information in the operating room. This is designed to improve lab layout and procedure efficiency. The system also features a remote viewing and recording capability called <i>Odyssey Cinema,</i> which is an innovative solution that delivers synchronized content for optimized workflow, advanced care, and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation, and training.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We promote our full suite of products in a typical hospital implementation, subject to regulatory approvals or clearances. This implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and ongoing software updates. In hospitals where our full suite of products has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have received regulatory clearances and registration approvals necessary for us to market the <i>Genesis RMN</i> System in the U.S. and Europe, and we are in the process of obtaining necessary registrations for extending our markets in other countries. The <i>Niobe</i> System, <i>Odyssey</i> Solution, <i>Cardiodrive</i>, and various disposable interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries. We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the <i>Vdrive</i> and <i>Vdrive Duo</i> Systems with the <i>V-CAS</i>, <i>V-Loop </i>and <i>V-Sono </i>devices in the U.S., Canada and Europe. Stereotaxis Imaging Model S x-ray System is CE marked and FDA cleared.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have strategic relationships with technology leaders and innovators in the global interventional market. Through these strategic relationships we provide compatibility between our robotic magnetic navigation system and digital imaging and 3D catheter location sensing technology, as well as disposable interventional devices. The maintenance of these strategic relationships, or the establishment of equivalent alternatives, is critical to our commercialization efforts. There are no guarantees that any existing strategic relationships will continue, and efforts are ongoing to ensure the availability of integrated systems and devices and/or equivalent alternatives. We cannot provide assurance as to the timeline of the ongoing availability of such compatible systems or our ability to obtain equivalent alternatives on competitive terms or at all.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zZtmAxNppcK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks and Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The novel coronavirus COVID-19 (“COVID-19”) pandemic has resulted, and is likely to continue to result, in significant, periodic disruptions to the economy, as well as business and capital markets around the world. The full extent of the impact of the COVID-19 pandemic on our business, results of operations and financial condition will depend on numerous evolving factors that we may not be able to accurately predict.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the COVID-19 outbreak, we have experienced business disruptions, including travel restrictions on us and our third-party distributors, which have negatively affected our complex sales, marketing, installation, distribution and service network relating to our products and services. The COVID-19 pandemic may continue to negatively affect demand for both our systems and our disposable products by limiting the ability of our sales personnel to maintain their customary contacts with customers as governmental authorities institute prolonged quarantines, travel restrictions, and shelter-in-place orders, or as our customers impose limitations on contacts and in-person meetings that go beyond those imposed by governmental authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, many of our hospital customers, for whom the purchase of our system involves a significant capital purchase which may be part of a larger construction project at the customer site (typically the construction of a new building), may themselves be under economic pressures. This may cause delays or cancellations of current purchase orders and other commitments and may exacerbate the long and variable sales and installation cycles for our robotic magnetic navigation systems. We may also experience significant reductions in demand for our disposable products as our healthcare customers (physicians and hospitals) continue to re-prioritize the treatment of patients and divert resources away from non-coronavirus areas, which we anticipate will lead to the performance of fewer procedures in which our disposable products are used. In addition, patients may consider foregoing or deferring procedures utilizing our products, even if physicians and hospitals are willing to perform them, which could also reduce demand for, and sales of, our disposable products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date of the filing of this Quarterly Report on Form 10-Q, we believe our manufacturing operations and supply chains have been manageably impacted, but we cannot guarantee that they will not be impacted more severely in the future. If our manufacturing operations or supply chains are materially interrupted, it may not be possible for us to timely manufacture relevant products at required levels, or at all. Changes in economic conditions and supply chain constraints could lead to higher inflation than previously experienced or expected, which could, in turn, lead to an increase in costs. We may be unable to raise the prices of our products sufficiently to keep up with the rate of inflation. A material reduction or interruption to any of our manufacturing processes or a substantial increase in costs would have a material adverse effect on our business, operating results, and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If governmental authorities around the world reinstitute prolonged mandatory closures, social distancing protocols and shelter-in-place orders, or as private parties on whom we rely to operate our business put in place their own protocols that go beyond those instituted by relevant governmental authorities, our ability to adequately staff and maintain our operations or further our product development could be negatively impacted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any disruption to the capital markets could negatively impact our ability to raise capital. If the capital markets are disrupted for an extended period of time and we need to raise additional capital, such capital may not be available on acceptable terms, or at all. Continued disruptions to the capital markets and other financing sources could also negatively impact our hospital customers’ ability to raise capital or otherwise obtain financing to fund their operations and capital projects. Such could result in delayed spending on current projects, a longer sales cycle for new projects where a large capital commitment is required, and decreased demand for our disposable products as well as an increased risk of customer defaults or delays in payments for our systems installation, service contracts and disposable products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We continue to evaluate and, where appropriate, take actions to reduce costs and spending across our organization. We will continue to actively monitor the situation and may take further actions that alter our business operations that may be required by federal, state, or local governmental authorities that may be implemented by our vendors, supplier or customers, or that we determine are in the best interests of our employees, customers, suppliers and stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.35in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4957000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15143000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8368000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	1500000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	1400000	usd
CY2022Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1500000	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1400000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7657000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9106000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20846000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26780000	usd
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	13900000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1005000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1007000	usd
CY2022Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	351000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	178000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	9459000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8515000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1416000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2238000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8043000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6277000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5600000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4800000	usd
CY2022Q3	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	200000	usd
CY2021Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	200000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4917000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4619000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14138000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7361000	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	339000	usd
CY2021Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	338000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76100007	shares
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2823000	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1879000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2165000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	8161000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4433000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5843000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3346000	usd
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75700389	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75977920	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75476381	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	6831000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3642000	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	384000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	133000	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2825000	usd
CY2022Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	599000	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1012000	usd
CY2022Q3	STXS	Prepaid Commissions Current And Noncurrent PrepaidCommissionsCurrentAndNoncurrent	213000	usd
CY2021Q4	STXS	Prepaid Commissions Current And Noncurrent PrepaidCommissionsCurrentAndNoncurrent	229000	usd
CY2022Q3	us-gaap	Deposits Assets DepositsAssets	640000	usd
CY2021Q4	us-gaap	Deposits Assets DepositsAssets	1276000	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	66000	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	117000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1518000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	2634000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	233000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	278000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1285000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2356000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6755000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3211000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3409000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2632000	usd
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	1000000.0	usd
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5900000	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5900000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y2M26D
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	227000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	733000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	678000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1898000	usd
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4000	usd
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	14000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	24000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	45000	usd
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	246000	usd
	us-gaap	Sublease Income SubleaseIncome	740000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	231000	usd
CY2021Q3	us-gaap	Lease Cost LeaseCost	501000	usd
	us-gaap	Lease Cost LeaseCost	702000	usd
	us-gaap	Lease Cost LeaseCost	1203000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	232000	usd
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	624000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	886000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1794000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	214000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	877000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	898000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	919000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	935000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4986000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8829000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2884000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	5945000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1492000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1516000	usd
CY2022Q3	STXS	Accrued Licenses And Maintenance Fees Current And Noncurrent AccruedLicensesAndMaintenanceFeesCurrentAndNoncurrent	484000	usd
CY2021Q4	STXS	Accrued Licenses And Maintenance Fees Current And Noncurrent AccruedLicensesAndMaintenanceFeesCurrentAndNoncurrent	484000	usd
CY2022Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	166000	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	242000	usd
CY2022Q3	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	269000	usd
CY2021Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	177000	usd
CY2022Q3	STXS	Accrued Investigational Sites AccruedInvestigationalSites	92000	usd
CY2021Q4	STXS	Accrued Investigational Sites AccruedInvestigationalSites	123000	usd
CY2022Q3	STXS	Accrued Lease Deposit Payable AccruedLeaseDepositPayable	5000	usd
CY2021Q4	STXS	Accrued Lease Deposit Payable AccruedLeaseDepositPayable	124000	usd
CY2022Q3	us-gaap	Contractual Obligation ContractualObligation	738000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	133000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	81000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3379000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2747000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	168000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	219000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3211000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2528000	usd
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of common stock are entitled to one vote for each share held and to receive dividends when and as declared by the Board of Directors out of funds legally available for dividends, subject to the prior rights or preferences applicable to any preferred stock as may then be outstanding
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	0	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5600000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2818012	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	766500	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.78
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	111791	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.44
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	233588	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.03
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3239133	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.29
	us-gaap	Investment Income Interest InvestmentIncomeInterest	200000	usd
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	242000	usd
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	158000	usd
	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	95000	usd
CY2021	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	199000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	171000	usd
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	115000	usd
CY2022Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	166000	usd
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	242000	usd

Files In Submission

Name	View Source	Status
0001493152-22-031744-index-headers.html	Edgar Link	pending
0001493152-22-031744-index.html	Edgar Link	pending
0001493152-22-031744.txt	Edgar Link	pending
0001493152-22-031744-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stxs-20220930.xsd	Edgar Link	pending
stxs-20220930_cal.xml	Edgar Link	unprocessable
stxs-20220930_def.xml	Edgar Link	unprocessable
stxs-20220930_pre.xml	Edgar Link	unprocessable
stxs-20220930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STXS
Stereotaxis, Inc. Stock $stxs

2022 Q4 Form 10-Q Financial Statement

#000149315222031744 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STXS Stereotaxis, Inc. Stock $stxs

2022 Q4 Form 10-Q Financial Statement

#000149315222031744 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STXS
Stereotaxis, Inc. Stock $stxs